Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2014 | Original Article

¹³¹I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

Authors: Chien-Mu Lin, Pat Doyle, Yu-Tse Tsan, Chang-Hsing Lee, Jung-Der Wang, Pau-Chung Chen, Health Data Analysis in Taiwan (hDATa) Research Group

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2014

Abstract

Purpose

To evaluate the association between ¹³¹I therapy for thyroid cancer and risk of developing primary hyperparathyroidism.

Methods

This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997–2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative ¹³¹I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of ¹³¹I therapy on the risk of developing primary hyperparathyroidism in the cohort.

Results

A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10⁵ person-years. ¹³¹I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02–1.86) and 0.46 (95% CI 0.10–2.10) for those receiving a cumulative ¹³¹I dose of 0.1–3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing ¹³¹I dose (test for trend p = 0.51). No interaction was found between ¹³¹I dose and age (p = 0.94) or ¹³¹I dose and sex (p = 0.99).

Conclusion

¹³¹I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.

Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145–58. doi:10.1016/S0140-6736(09)60507-9.PubMedCrossRef

Chen HH, Chen YW, Wu CJ. Primary hyperparathyroidism in Taiwan: clinical features and prevalence in a single-center experience. Endocrine. 2010;37(2):373–8. doi:10.1007/s12020-010-9315-7.PubMedCrossRef

Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Amy Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122–9. doi:10.1210/jc.2012-4022.PubMedCrossRef

Tisell LE, Carlsson S, Fjalling M, Hansson G, Lindberg S, Lundberg LM, et al. Hyperparathyroidism subsequent to neck irradiation. Risk factors. Cancer. 1985;56(7):1529–33.PubMedCrossRef

Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose–response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(1):254–7.PubMed

Holmberg E, Wallgren A, Holm LE, Lundell M, Karlsson P. Dose–response relationship for parathyroid adenoma after exposure to ionizing radiation in infancy. Radiat Res. 2002;158(4):418–23.PubMedCrossRef

Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA. 1990;264(5):581–4.PubMedCrossRef

Fujiwara S, Sposto R, Ezaki H, Akiba S, Neriishi K, Kodama K, et al. Hyperparathyroidism among atomic bomb survivors in Hiroshima. Radiat Res. 1992;130(3):372–8.PubMedCrossRef

Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid as a target for radiation damage. N Engl J Med. 2011;365(7):676–8. doi:10.1056/NEJMc1104982.PubMedCrossRef

10.

Bondeson AG, Bondeson L, Thompson NW. Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence? Surgery. 1989;106(6):1025–7.PubMed

11.

Rasmuson T, Tavelin B. Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncol. 2006;45(8):1059–61. doi:10.1080/02841860500516618.PubMedCrossRef

12.

Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514–21. doi:10.1200/JCO.2012.44.6831.PubMedCrossRef

13.

Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4. doi:10.1016/S1470-2045(11)70165-6.PubMedCrossRef

14.

Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 2011;29(22):3001–7. doi:10.1200/JCO.2011.35.1908.PubMedCrossRef

15.

Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol. 2010;28(18):2952–7. doi:10.1200/JCO.2009.26.0695.PubMedCrossRef

16.

Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–86. doi:10.1093/jnci/djp467.PubMedCrossRef

17.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214. doi:10.1089/thy.2009.0110.PubMedCrossRef

18.

Colaco SM, Si M, Reiff E, Clark OH. Hyperparathyroidism after radioactive iodine therapy. Am J Surg. 2007;194(3):323–7. doi:10.1016/j.amjsurg.2007.04.005.PubMedCrossRef

19.

Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83(12):2638–48. doi:10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2–1.PubMedCrossRef

20.

Cancer registry annual report (2008) Bureau of Health Promotion, Department of Health, Taiwan.

21.

Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–39. doi:10.1089/thy.2012.0302.PubMedCrossRef

22.

Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612. doi:10.1089/thy.2008.0403.PubMedCrossRef

Title: 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study
Authors: Chien-Mu Lin
Pat Doyle
Yu-Tse Tsan
Chang-Hsing Lee
Jung-Der Wang
Pau-Chung Chen
Health Data Analysis in Taiwan (hDATa) Research Group
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2541-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹³¹I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI

Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT

Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain